publication date: Apr. 17, 2020

In Brief

J. Alan Diehl named deputy director and chief operating officer of Case CCC

J. Alan Diehl was named deputy director and chief operating officer of the Case Comprehensive Cancer Center.

Diehl will work closely with Stan Gerson, director of Case Comprehensive Cancer Center,  to coordinate activities based on the recently updated strategic plan, priorities identified by the executive committee Diehl has been a member of, and to lead multi-investigator initiatives and grant applications.

Diehl joined Case Western Reserve University in 2019 as  chair of the Department of Biochemistry in the School of Medicine. Diehl was director of the Cancer Cell Biology Program at the Abramson Family Cancer Research Institute at the University of Pennsylvania, and most recently served as associate director of basic science at Hollings Cancer Center at the Medical University of South Carolina.

Diehl’s research focuses on the discovery of molecular mechanisms that contribute to uncontrolled cell proliferation and decreased cell death. He is an expert in Program Project Grants and has already advised Case CCC member groups gearing toward submissions. Diehl also serves on multiple External Advisory Boards for NCI-designated cancer centers.


Andres F. Correa joins Fox Chase Cancer Center

Andres F. Correa will join Fox Chase Cancer Center as an assistant professor in the Department of Surgery in the Urologic Oncology Division starting May 4.

Correa, who was a Society of Urologic Oncology Fellow at Fox Chase, is returning to the center after serving as attending surgeon and assistant professor in the division of urology in the department of surgery at MD Anderson Cancer Center at Cooper University Hospital.

Correa is skilled at surgical modalities including robotics, laparoscopy, and traditional open surgery, and has expertise in prostate, kidney, bladder, testicular, and other genitourinary cancers.


Esther Welkowsky named VP, clinical operations, at Elicio Therapeutics

Esther Welkowsky was named  vice president of Clinical Operations at Elicio Therapeutics, a next generation immuno-oncology company. Welkowsky has managed clinical operations teams for oncology clinical trials and was most recently executive director of Clinical Operations at Allogene.

Copyright (c) 2020 The Cancer Letter Inc.